Synthetic Retrotransposon Gene Codon Optimization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current transposon and retrotransposon technologies have limitations in gene therapy applications due to low expression levels and inefficient transposition, which hampers their utility in correcting genetic disorders and manipulating mammalian genomes effectively.
Innovation Solution
Development of synthetic transposon and retrotransposon genes, specifically optimized ORF1 and ORF2 genes, that utilize human-associated codons for enhanced expression and efficiency, incorporating unique restriction sites for improved subcloning and vector constructs for increased retrotransposition frequencies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If native retrotransposon elements are used for gene therapy, then the system maintains natural genomic compatibility, but the expression levels and retrotransposition efficiency remain low
Solution Approach 1:
The patent applies parameter changes by optimizing codon usage to match human-associated preferences, modifying the nucleotide sequence while preserving the amino acid sequence. This recoding strategy increases expression levels and retrotransposition efficiency without altering the functional protein products, directly resolving the contradiction between maintaining natural compatibility and improving productivity.
Solution Approach 2:
The patent creates synthetic copies of retrotransposon genes with optimized sequences. By synthesizing new gene versions with improved codon usage and incorporating unique restriction sites, the invention produces enhanced copies that maintain functional compatibility while achieving superior expression and retrotransposition efficiency compared to native elements.
2Quantity of substance
If synthetic genes with optimized codons are used, then expression levels increase, but the manufacturing and design complexity increases
Solution Approach 1:
The patent implements self-service by incorporating unique restriction sites at predetermined positions within the synthetic genes. These built-in molecular features enable automated subcloning and vector construction without requiring complex manual manipulation, thereby reducing manufacturing complexity despite the advanced gene design. The restriction sites allow standard molecular biology techniques to efficiently assemble the optimized genes into functional vectors.
3Ease of operation
If unique restriction sites are incorporated for subcloning, then vector construction efficiency improves, but the gene sequence complexity increases
Solution Approach 1:
The patent applies preliminary action by pre-incorporating unique restriction sites during the gene synthesis stage. This advance preparation enables straightforward subcloning and vector construction in subsequent steps, as the restriction sites are already positioned and ready for standard enzymatic digestion and ligation procedures. The preliminary inclusion of these features simplifies downstream operations despite adding to the initial sequence design complexity.
Data Source
AI summary
The invention relates to synthetic transposon and retrotransposon genes that exhibit higher levels of expression relative to natural transposon and retrotransposon genes. The invention further relates to transposons and retrotransposons comprising such synthetic genes.